Correlation Between OnKure Therapeutics, and Vigil Neuroscience

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both OnKure Therapeutics, and Vigil Neuroscience at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining OnKure Therapeutics, and Vigil Neuroscience into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between OnKure Therapeutics, and Vigil Neuroscience, you can compare the effects of market volatilities on OnKure Therapeutics, and Vigil Neuroscience and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in OnKure Therapeutics, with a short position of Vigil Neuroscience. Check out your portfolio center. Please also check ongoing floating volatility patterns of OnKure Therapeutics, and Vigil Neuroscience.

Diversification Opportunities for OnKure Therapeutics, and Vigil Neuroscience

0.3
  Correlation Coefficient

Weak diversification

The 3 months correlation between OnKure and Vigil is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding OnKure Therapeutics, and Vigil Neuroscience in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vigil Neuroscience and OnKure Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on OnKure Therapeutics, are associated (or correlated) with Vigil Neuroscience. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vigil Neuroscience has no effect on the direction of OnKure Therapeutics, i.e., OnKure Therapeutics, and Vigil Neuroscience go up and down completely randomly.

Pair Corralation between OnKure Therapeutics, and Vigil Neuroscience

Given the investment horizon of 90 days OnKure Therapeutics, is expected to generate 0.49 times more return on investment than Vigil Neuroscience. However, OnKure Therapeutics, is 2.06 times less risky than Vigil Neuroscience. It trades about -0.24 of its potential returns per unit of risk. Vigil Neuroscience is currently generating about -0.3 per unit of risk. If you would invest  1,787  in OnKure Therapeutics, on August 30, 2024 and sell it today you would lose (311.00) from holding OnKure Therapeutics, or give up 17.4% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy95.65%
ValuesDaily Returns

OnKure Therapeutics,  vs.  Vigil Neuroscience

 Performance 
       Timeline  
OnKure Therapeutics, 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in OnKure Therapeutics, are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable basic indicators, OnKure Therapeutics, is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
Vigil Neuroscience 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vigil Neuroscience has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

OnKure Therapeutics, and Vigil Neuroscience Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with OnKure Therapeutics, and Vigil Neuroscience

The main advantage of trading using opposite OnKure Therapeutics, and Vigil Neuroscience positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if OnKure Therapeutics, position performs unexpectedly, Vigil Neuroscience can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vigil Neuroscience will offset losses from the drop in Vigil Neuroscience's long position.
The idea behind OnKure Therapeutics, and Vigil Neuroscience pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences